🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. A Study of LY3200882 in Participants With Solid Tumors.

    Eli Lilly Co.

    Metastatic cancer, Solid Tumor

    phase 1 other active

    1 trial

  2. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

    Eli Lilly Co.

    Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer SMARCA4-Deficient Tumor

    phase 1 other active

    1 trial

  3. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    Eli Lilly Co.

    Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

    phase 1 other active

    1 trial

  4. A Study of LY4175408 in Participants With Advanced or Metastatic Solid Tumors.

    Eli Lilly Co.

    Cancer

    phase 1 other active

    1 trial

  5. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    Eli Lilly Co.

    Breast Neoplasms Colorectal Neoplasms Prostate Neoplasm Endometrial Neoplasms Neoplasm Metastasis

    phase 1 other active

    1 trial

  6. A Study of PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors

    Pfizer Australia Pty Ltd

    Melanoma (or) malignant melanoma Non-small cell lung cancer Head and neck squamous cell carcinoma Esophageal cancer

    phase 1 other active

    1 trial

  7. A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Compared to Oral Lenvatinib Capsules in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

    AbbVie Deutschland GmbH & Co. KG

    Squamous-Cell Non-Small Cell Lung Cancer, Hepatocellular Cancer

    phase 1 other active

    1 trial

  8. A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

    AbbVie Deutschland GmbH & Co. KG

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  9. A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

    AbbVie Deutschland GmbH & Co. KG

    Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer

    phase 1 other active

    1 trial

  10. A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

    Alphapharm Pty Ltd

    Arm A: Diagnosed with uterine serous carcinoma (USC) Arm B: Diagnosed with recurrent or progressive, high-grade epithelial ovarian cancer (EOC) with cyclin E1-driven selection Arm C: Diagnosed with solid tumor with biomarker-driven selection

    phase 1 other active

    1 trial

  11. A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations (FURTHER)

    ArriVent BioPharma

    Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 kinase domain mutations

    phase 1 other active

    1 trial

  12. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  13. A Study to Learn About How Different Formulations of the Medicine Called Mevrometostat are Taken up Into the Blood in Healthy Adult Participants

    Pfizer Australia Pty Ltd

    Small cell lung cancer, Castration-resistant prostate cancer, Follicular lymphoma

    phase 1 other active

    1 trial

  14. A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed by the Body in Men With Prostate Cancer

    Astellas Pharma GmbH

    Hot Flush

    phase 1 other active

    1 trial

  15. A Study to Learn How a Tablet Compared with an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up into the Blood in Healthy Adults.

    Pfizer Australia Pty Ltd

    ER+/HER2- breast cancer

    phase 1 other active

    1 trial

  16. A Study to Learn If The Study Medicine Called Fluconazole Changes How the Body Processes The Other Study Medicine PF-07248144

    Pfizer Australia Pty Ltd

    locally advanced or metastatic HR+/HER2- breast cancer

    phase 1 other active

    1 trial

  17. A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam

    Pfizer Australia Pty Ltd

    ER+/HER2 positive breast cancer

    phase 1 other active

    1 trial

  18. A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers.

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory B-cell Malignancies

    phase 1 other active

    1 trial

  19. A Study to Learn how Various Tablets of the Study Medicine Called Vepdegestrant are Taken up into the Blood in Healthy Adults

    Pfizer Australia Pty Ltd

    ER+/HER2- Breast Cancer

    phase 1 other active

    1 trial

  20. A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144

    Pfizer Australia Pty Ltd

    locally advanced or metastatic ER+/HER2- breast cancer

    phase 1 other active

    1 trial

  21. A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

    Boehringer Ingelheim

    non-small cell lung cancer or, melanoma, head and neck squamous cell carcinoma

    phase 1 other active

    1 trial

  22. A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants with Advanced Solid Tumors

    Hoffmann-La Roche

    Advanced Solid Tumors Harboring RAS Mutation(S)

    phase 1 other active

    1 trial

  23. A Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors

    AbbVie Deutschland GmbH & Co. KG

    Patients with relapsed or refractory solid tumors, including: Small cell lung cancer (SCLC); Non-small cell cancer (NSCLC); Breast cancer

    phase 1 other active

    1 trial

  24. A clinical study to evaluate the efficacy of ceritinib in combination with nivolumab in patients with ALK positive lung cancer

    Novartis Pharmaceuticals

    Non-small cell lung cancer

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources